NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (“Sarepta” or the “Company”). Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta’s most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. A